Efficacy of leukocyte- and platelet-rich plasma gel (L-PRP gel) in treating osteomyelitis in a rabbit model

Journal of Orthopaedic Research

Volumn 31, Issue 6, 2013, Pages 949-956

  Li, Guang Yi ^a   Yin, Ji Min ^a   Ding, Hao ^a   Jia, Wei Tao ^a   Zhang, Chang Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

antimicrobial proteins; L PRP gel; MRSA; osteomyelitis; vancomycin

Indexed keywords

VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BONE REGENERATION; CONTROLLED STUDY; DEBRIDEMENT; GEL; HISTOLOGY; IN VIVO STUDY; LEUKOCYTE AND PLATELET RICH PLASMA GEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTE COUNT; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; PLATELET-RICH PLASMA; RABBITS; STAPHYLOCOCCAL INFECTIONS; TIBIA; VANCOMYCIN;

EID: 84876287664     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22299     Document Type: Article

References (45)

1. Lazzarini L, Mader JT, Calhoun JH,. 2004. Osteomyelitis in long bones. J Bone Joint Surg Am 86-A: 2305-2318.
2. Shuford JA, Steckelberg JM,. 2003. Role of oral antimicrobial therapy in the management of osteomyelitis. Curr Opin Infect Dis 16: 515-519.
3. Sheehy SH, Atkins BA, Bejon P, et al. 2010. The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens. J Infect 60: 338-343.
4. Zalavras CG, Patzakis MJ, Holtom P,. 2004. Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res 427: 86-93.
5. Zelken J, Wanich T, Gardner M, et al. 2007. PMMA is superior to hydroxyapatite for colony reduction in induced osteomyelitis. Clin Orthop Relat Res 462: 190-194.
6. Hanssen AD, Spangehl MJ,. 2004. Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements. Clin Orthop Relat Res 427: 79-85.
7. Nelson CL,. 2004. The current status of material used for depot delivery of drugs. Clin Orthop Relat Res 427: 72-78.
8. Marx RE,. 2001. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 10: 225-228.
9. Alsousou J, Thompson M, Hulley P, et al. 2009. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 91: 987-996.
10. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T,. 2009. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 27: 158-167.
11. Dohan Ehrenfest DM, Bielecki T, Mishra A, et al. 2012. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol 13: 1131-1137.
12. Frechette JP, Martineau I, Gagnon G,. 2005. Platelet-rich plasmas: growth factor content and roles in wound healing. J Dent Res 84: 434-439.
13. Bielecki T, Gazdzik TS, Szczepanski T,. 2006. Re: the effects of local platelet rich plasma delivery on diabetic fracture healing. What do we use: platelet-rich plasma or platelet-rich gel? Bone 39: 1388; author reply 1389.
14. Wrotniak M, Bielecki T, Gazdzik TS,. 2007. Current opinion about using the platelet-rich gel in orthopaedics and trauma surgery. Ortop Traumatol Rehabil 9: 227-2238.
15. Jia WT, Zhang CQ, Wang JQ, et al. 2010. The prophylactic effects of platelet-leucocyte gel in osteomyelitis: an experimental study in a rabbit model. J Bone Joint Surg Br 92: 304-310.
16. Nijhof MW, Stallmann HP, Vogely HC, et al. 2000. Prevention of infection with tobramycin-containing bone cement or systemic cefazolin in an animal model. J Biomed Mater Res 52: 709-715.
17. Norden CW, Myerowitz RL, Keleti E,. 1980. Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis. Br J Exp Pathol 61: 451-460.
18. Smeltzer MS, Thomas JR, Hickmon SG, et al. 1997. Characterization of a rabbit model of Staphylococcal osteomyelitis. J Orthop Res 15: 414-421.
19. Waldvogel FA, Medoff G, Swartz MN,. 1970. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 282: 198-206.
20. Lew DP, Waldvogel FA,. 2004. Osteomyelitis. Lancet 364: 369-379.
21. Sakoulas G, Moellering RC Jr., 2008. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 46: S360-S367.
22. Calhoun JH, Mader JT,. 1997. Treatment of osteomyelitis with a biodegradable antibiotic implant. Clin Orthop Relat Res 341: 206-214.
23. Mehta S, Watson JT,. 2008. Platelet rich concentrate: basic science and current clinical applications. J Orthop Trauma 22: 432-438.
24. Bielecki TM, Gazdzik TS, Arendt J, et al. 2007. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study. J Bone Joint Surg Br 89: 417-420.
25. Moojen DJ, Everts PA, Schure RM, et al. 2008. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 26: 404-410.
26. Carter MJ, Fylling CP, Parnell LK,. 2011. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty 11: e38.
27. Wang HF, Gao YS, Yuan T, et al. 2012. Chronic calcaneal osteomyelitis associated with soft-tissue defect could be successfully treated with platelet-rich plasma: a case report. Int Wound J DOI: 10.1111/j.1742-481X.2012. 00951.x. [Epub ahead of print].
28. Yuan T, Zhang C, Zeng B,. 2008. Treatment of chronic femoral osteomyelitis with platelet-rich plasma (PRP): a case report. Transfus Apher Sci 38: 167-173.
29. Yeaman MR,. 2010. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 67: 525-544.
30. Hancock RE,. 1997. Peptide antibiotics. Lancet 349: 418-422.
31. Bielecki T, Gazdzik TS,. 2009. Antimicrobial activity of platelet-rich gel after antibiotic administration-a preliminary report. J Bone Joint Surg Br 91-B: 131.
32. Eppley BL, Woodell JE, Higgins J,. 2004. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 114: 1502-1508.
33. Foster TE, Puskas BL, Mandelbaum BR, et al. 2009. Platelet-rich plasma from basic science to clinical applications. Am J Sport Med 37: 2259-2272.
34. Thomas MV, Puleo DA,. 2011. Infection, inflammation, and bone regeneration: a paradoxical relationship. J Dent Res 90: 1052-1061.
35. Dohan DM, Choukroun J, Diss A, et al. 2006. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101: e45-e50.
36. Rubin R, Baserga R,. 1995. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73: 311-331.
37. Szczepanski T, van der Velden VH, Hoogeveen PG, et al. 2004. Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 103: 3798-3804.
38. Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, et al. 2007. Why the platelet-rich gel has antimicrobial activity? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 303-305.
39. Dohan DM, Choukroun J, Diss A, et al. 2006. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101: e51-e55.
40. Wiesner J, Vilcinskas A,. 2010. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 1: 440-464.
41. Borregaard N, Sorensen OE, Theilgaard-Monch K,. 2007. Neutrophil granules: a library of innate immunity proteins. Trends Immunol 28: 340-345.
42. Risso A,. 2000. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukoc Biol 68: 785-792.
43. Werther K, Christensen IJ, Nielsen HJ,. 2002. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 62: 343-350.
44. Nielsen HJ, Werther K, Mynster T, et al. 2001. Bacteria-induced release of white cell- and platelet-derived vascular endothelial growth factor in vitro. Vox Sang 80: 170-178.
45. Dohan Ehrenfest DM, Bielecki T, Jimbo R, et al. 2012. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol 13: 1145-1152.